Your browser doesn't support javascript.
loading
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.
Haddad, Fadi G; Sasaki, Koji; Bidikian, Aram; Issa, Ghayas C; Kadia, Tapan; Jain, Nitin; Alvarado, Yesid; Short, Nicholas J; Pemmaraju, Naveen; Loghavi, Sanam; Patel, Keyur P; Kanagal-Shamanna, Rashmi; Yilmaz, Musa; Masarova, Lucia; Jabbour, Elias; Kantarjian, Hagop.
Afiliación
  • Haddad FG; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Sasaki K; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Bidikian A; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Issa GC; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Kadia T; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Jain N; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Alvarado Y; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kanagal-Shamanna R; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Yilmaz M; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Masarova L; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Jabbour E; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
  • Kantarjian H; Department of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol ; 98(10): 1619-1626, 2023 10.
Article en En | MEDLINE | ID: mdl-37485584
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridazinas / Leucemia Mielógena Crónica BCR-ABL Positiva Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Am J Hematol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridazinas / Leucemia Mielógena Crónica BCR-ABL Positiva Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Am J Hematol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos